TG Therapeutics (CH:NKB2)
NASDAQ:NKB2
NKB2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high gross and net margins reflect strong product economics for BRIUMVI and operating leverage across the business. Durable margins support reinvestment in commercialization and R&D, underpinning long‑term ability to fund growth and return capital without reliance on price multiple expansion.
Commercial Momentum & AdoptionRapid, repeatable patient adoption and a rising share of treatment‑naive starts indicate durable demand and expanding market penetration. Strong real‑world uptake creates recurring revenue, strengthens payer/provider relationships, and reduces commercialization risk versus new product launches over the next several quarters.
Improved Balance SheetA materially de‑levered balance sheet with minimal debt and a larger asset base gives the company financial flexibility to fund Phase III, manufacturing scale‑up, and lifecycle investments. This reduces refinancing risk and supports strategic optionality across the 2–6 month horizon and beyond.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow despite strong net income weakens earnings quality and signals working‑capital or non‑cash drivers. If cash conversion does not improve, the company may need to draw on reserves or alter capital plans, constraining durable self‑funding for growth initiatives.
High Gross‑to‑Net PressureA structural ~65% gross‑to‑net rate meaningfully reduces realized revenue and margin sustainability versus list sales, concentrating payer and rebate risk. High deductions make long‑term revenue growth and cash flow more sensitive to payer dynamics and negotiation outcomes.
Clinical & Regulatory Execution RiskFuture upside depends on successful readouts and regulatory steps for single‑infusion and subcutaneous launches. Delays, negative outcomes, or additional bridging/device requirements would slow addressable market expansion and revenue diversification, posing a multi‑quarter execution risk to the company’s growth thesis.
TG Therapeutics News
NKB2 FAQ
What was TG Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is TG Therapeutics’s market cap?
Currently, no data Available
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.095 earnings per share for the quarter, missing the consensus estimate of $0.217 by -$0.122.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.28.
How many shares outstanding does TG Therapeutics have?
Currently, no data Available
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.095 in its last earnings report, missing expectations of $0.217. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in CH:NKB2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.34%
12-Months-Change
Fundamentals
Return on Equity
87.36%
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
NKB2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.View all CH:NKB2 earnings summariesNKB2 Stock 12 Month Forecast
Average Price Target
$37.60
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Options Prices
Currently, No data available
---